Capital successfully raised $800 million ($240 million in equity and $560 million in debt) for its first managed fund, Drug Royalty I. With the raising of Drug Royalty I, DRI completed its transition to a private equity fund manager business model. In 2010, DRI successfully raised $926 million of capital commitments ($701 million in equity for its second managed fund, Drug Royalty II, and $225 million in equity for Drug Royalty II Co-Investment Fund). As of June 30, 2012, Drug Royalty I and Drug Royalty II have collectively acquired 40 separate international royalty streams from inventors, universities, research institutes, biotechnology and global pharmaceutical companies payable on 29 different leading pharmaceutical products. Today DRI Capital is a fully-integrated team of 30 professionals and support staff with approximately $2 billion under management, focused on identifying, assessing, acquiring and managing biopharmaceutical royalty assets across the globe.